Rifampicin
- Generic Name
- Rifampicin
- Brand Names
- Isonarif, Rifadin, Rifamate, Rifater, Rofact
- Drug Type
- Small Molecule
- Chemical Formula
- C43H58N4O12
- CAS Number
- 13292-46-1
- Unique Ingredient Identifier
- VJT6J7R4TR
- Background
A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericid...
- Indication
Rifampin is indicated for the treatment of tuberculosis and tuberculosis-related mycobacterial infections. In combination with pyrazinamide and isoniazid, it is used in the initial phase of the short-course treatment of pulmonary tuberculosis.
- Associated Conditions
- Cholestatic pruritus, MRSA Infections, Prosthetic Joint Infections, Asymptomatic Neisseria meningitidis carrier of the nasopharynx, Initial phase Tuberculosis, Late phase Tuberculosis
- Associated Therapies
- Antibacterial therapy
Persistent Methicillin Resistant Staphylococcus Aureus Eradication Protocol (PMEP)
- First Posted Date
- 2012-05-09
- Last Posted Date
- 2019-02-26
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 29
- Registration Number
- NCT01594827
- Locations
- 🇺🇸
Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
🇺🇸Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States
A Drug-Drug Interaction Study of Ketoconazole, Rifampicin and Ritonavir-Boosted Atazanavir With Single-Dose RO5093151 in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2012-05-04
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 51
- Registration Number
- NCT01591850
Essentiality of INH in TB Therapy
- Conditions
- Interventions
- First Posted Date
- 2012-05-02
- Last Posted Date
- 2018-04-06
- Target Recruit Count
- 69
- Registration Number
- NCT01589497
- Locations
- 🇿🇦
TASK Applied Science CRS (31718), Bellville, South Africa
🇿🇦University of Cape Town Lung Institute (UCTLI) CRS (31792), Cape Town, Western Cape, South Africa
Colistin and Rifampicin for MDR-Acinetobacter
- First Posted Date
- 2012-04-16
- Last Posted Date
- 2012-04-16
- Lead Sponsor
- University of Campania "Luigi Vanvitelli"
- Target Recruit Count
- 210
- Registration Number
- NCT01577862
Study in Healthy Volunteers to Investigate the Effects of Rifampin on the Pharmacokinetics of NKTR-118
- First Posted Date
- 2012-02-15
- Last Posted Date
- 2014-10-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 22
- Registration Number
- NCT01533870
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States
Pharmacokinetics Study of Oral IXAZOMIB in Participants With Advanced Nonhematologic Malignancies or Lymphoma
- First Posted Date
- 2011-10-18
- Last Posted Date
- 2017-11-01
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 112
- Registration Number
- NCT01454076
Safety and Pharmacokinetics of Single and Multiple Dose Rifampin in Infants
- First Posted Date
- 2011-09-27
- Last Posted Date
- 2012-09-14
- Lead Sponsor
- University of North Carolina, Chapel Hill
- Target Recruit Count
- 2
- Registration Number
- NCT01441206
- Locations
- 🇺🇸
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
Randomized Controlled Trial of Standard Versus Systemic Decolonization Therapy for the Eradication of Methicillin-resistant Staphylococcus Aureus (MRSA) Colonization
- Conditions
- Interventions
- First Posted Date
- 2011-09-22
- Last Posted Date
- 2020-02-17
- Lead Sponsor
- Horizon Health Network
- Target Recruit Count
- 100
- Registration Number
- NCT01438515
- Locations
- 🇨🇦
Saint John Regional Hospital, Saint John, New Brunswick, Canada
Pharmacokinetic Drug Interaction Study in Healthy Male Subjects
- First Posted Date
- 2011-09-01
- Last Posted Date
- 2011-09-01
- Lead Sponsor
- LG Life Sciences
- Target Recruit Count
- 24
- Registration Number
- NCT01426906
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
The Effect of Intermittent Rifampicin on Raltegravir
- Conditions
- First Posted Date
- 2011-08-29
- Last Posted Date
- 2013-10-31
- Lead Sponsor
- Helen Reynolds
- Target Recruit Count
- 18
- Registration Number
- NCT01424826
- Locations
- 🇬🇧
Royal Liverpool & Broadgreen Univeristy Hospitals NHS Trust, Liverpool, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.